Cardiovascular Indication definition

Cardiovascular Indication means, with respect to any pharmaceutical product, an indication that has been granted Regulatory Approval (or, as applicable, for which Regulatory Approval is being sought or is intended to be sought) for the cure, mitigation, treatment or prevention of any cardiovascular disease, condition or symptom in humans, including dyslipidemia and other related metabolic disorders.

Cardiovascular Indication means the prevention, treatment, or amelioration of any cardiovascular disease or condition, including atherosclerosis, heart failure, myocardial infarction, acute coronary syndrome, myocarditis, angina, restenosis, aneurysms, vasculitis, complications of vascular surgery and heart surgery, thrombosis, phlebitis, peripheral vascular disease, and hypertension.

Cardiovascular Indication means indications for congestive heart failure and peripheral vascular diseases associated with congestive heart failure, and cardiac diseases.

Examples of Cardiovascular Indication in a sentence

• Except as may otherwise be agreed to by the Parties or required by other contractual obligations of PRONOVA, the Intellectual Property Rights shall automatically be deemed to include any PRONOVA Improvement relating to the use for a Cardiovascular Indication of any prescription or OTC pharmaceutical product containing Omega-3 fatty acids as an active ingredient.

• No later than thirty (30) days following the Initiation by Licensor of the first Phase III Clincal Study for a Collaboration Compound in the Cardiovascular Indication, Licensee shall pay Licensor a milestone payment equal to One Hundred Million Dollars ($100,000,000); Such payment shall be noncreditable against any other payments due hereunder.

• No later than thirty (30) days following the later of the Initiation by Licensor of the first Phsae II Clincial Study for a Collaboration Compound in the Cardiovascular Indication and Licensee’s exercise of the Collaboration Candidate Option for the Collaboration Compound that is the subject of the Phase II Clincial Study, Licensee shall pay Licensor a milestone payment equal to Fifty Million Dollars ($50,000,000).

• No later than thirty (30) days following Licensee’s filing of the first MAA for a Licensed Product containing a Collaboration Compound for the Cardiovascular Indication with the EMA, Licensee shall pay Licensor a milestone payment equal to Fifty Million Dollars ($50,000,000).

• No later than thirty (30) days following the receipt by Licensee of Regulatory Approval in each Major Market for a Licensed Product containing a Collaboration Compound, which approval includes an approval for the Cardiovascular Indication, in each of the five (5) Major Markets, Licensee shall pay Licensor the following milestone payment for each such country.

More Definitions of Cardiovascular Indication

Cardiovascular Indication or “CVD Indication” means, with respect to any pharmaceutical product, an indication for which Regulatory Approval has been granted, or is intended to be sought, for the treatment or prevention of any cardiovascular disease or condition that are not associated with diabetes or obesity.

Cardiovascular Indication means the prevention, treatment, or amelioration of any cardiovascular disease or condition, including atherosclerosis, heart failure, myocardial infarction, acute coronary syndrome, myocarditis, angina, restenosis, aneurysms, vasculitis, complications of vascular surgery and heart surgery, thrombosis, phlebitis, peripheral vascular disease, and hypertension. Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***].

Cardiovascular Indication means any indication included in Section 1.51(iii).